Cardio Thoracic Articles & Analysis
30 news found
TeraRecon, a ConcertAI company and a leader in advanced medical visualization using AI to improve patient care, today announced U.S.-based DocPanel, the world’s first radiology marketplace offering access to over 500 fellowship trained radiologists available for radiological reads, second opinions, and educational consults, has signed a contract for TeraRecon’s advanced visualization ...
Terumo Aortic today announced that the US Food and Drug Administration (FDA) has granted approval of the Thoraflex Hybrid Frozen Elephant Trunk (FET) device for commercial sale in the United States for the treatment of patients with complex aortic arch disease. Thoraflex Hybrid is the first of its kind device used in Frozen Elephant Trunk (FET) repair in the United States and was granted ...
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces its participation in two upcoming investor conferences. CytoSorbents will present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum on Thursday, November 18, 2021. Dr. ...
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that it has registered a new subsidiary, CytoSorbents Medical UK Limited, with plans to establish a direct sales presence within the United Kingdom (UK) and Ireland. CytoSorbents previously sold CytoSorb® via ...
EchoPixel has had a long-standing relationship with Stanford physicians, who were early adopters of its technology, beginning with the successful surgery of the conjoined Sandoval twins in 2017. The affiliation has continued in partnership with Michael Ma, MD, Assistant Professor of Cardiothoracic Surgery in the Division of Pediatric Cardiac Surgery at Stanford University, who has used ...
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that it has received approximately $740,000, net of transactions costs, in cash proceeds from the sale of its 2020 Net Operating Loss (NOL) and R&D tax credits from the Technology Business Tax Certificate ...
Lightpoint Medical today announced that Dr. Doug Adams, a specialist in robotic thoracic surgery at Bethesda North Hospital (part of TriHealth, Ohio) performed a first-in-the-world lung procedure with SENSEI, the company's new miniature robotic gamma probe. SENSEI is smaller than an AA battery and designed specifically for robotic and minimally-invasive surgery. The miniature size and ...
Anteris Technologies Ltd (ASX: AVR) reports the first-in-human DurAVR™ THV study met or exceeded its interim study objectives. At the 30-day follow up point, the first five patients of the planned 10-patient study showed: All five subjects continued to do well with no reported adverse events (no death, stroke, myocardial infarction, reintervention). An average 86% improvement in mean ...
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces the appointment of Professor Daniel Wendt, MD, PhD, MHBA, FETCS as Vice President, Medical Affairs Cardiovascular commencing January 1, 2022. Dr. Wendt is an internationally renowned academic cardiac surgeon with over ...
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the publication of results from the Company’s U.S. CytoSorb Therapy in COVID-19 (CTC) retrospective registry in the peer-reviewed journal, Frontiers in Medicine. ...
Aatru Medical, LLC ("Aatru") today announced the successful completion of the first 14 patients in their multi-center New Zealand-based clinical study of the FDA-approved NPSIMS™ Negative Pressure Surgical Incision Management System. The full Study enrollment will include plastic surgery, spinal surgery and cardiothoracic surgery closed incisions. The NPSIMS™, which contains no ...
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced today that the first patient has been enrolled in the Safe and Timely Antithrombotic Removal-Ticagrelor (STAR–T) double-blind, randomized, controlled clinical trial ...
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the full approval of its Investigational Device Exemption (IDE) application by the FDA to conduct the pivotal STAR–D (Safe and Timely Antithrombotic Removal – Direct ...
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification, announced the public availability of preliminary data abstracts from two separate endocarditis studies, including the REMOVE study, to be presented at the upcoming European Association for ...
The implant was performed at Hannover Medical School. Paris, July 26, 2021 – 6:00 pm CEST CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, today announces the first implant of its Aeson® bioprosthetic artificial ...
ByCarmat
“Data from 18 patients implanted with the Xeltis restorative pulmonary valve as part of other ongoing clinical trials are very promising,” said Professor Tomasz Mroczek, cardio-thoracic surgeon at the Polish-American Children's Hospital in Krakow, Poland. ...
AdjuCor raises € 29 million to enable its next phase of bringing its revolutionary heart assist technology to the severely underserved end-stage heart failure patients. This Series B financing round includes € 25 million from the cardiovascular-focused medical device platform company MitrAssist Holdings Limited accompanied by an additional € 4 million from the returning investor ...
VIDA Diagnostics, Inc. (“VIDA”), the leader in lung and respiratory intelligence, today announced a new strategic partnership with Peoria, Illinois-OSF HealthCare that will make VIDA Insights available to care teams across the organization. VIDA and its comprehensive, lung intelligence solutions continue to gain traction among integrated delivery network (IDN) health care providers ...
BioTrace Medical, Inc., the leader in innovative temporary cardiac pacing technology, today announced the company’s Tempo Temporary Pacing Lead was featured in a patient case series presented at the Society of Cardiovascular Anesthesiologists’ 43rd Annual Meeting and Workshops, taking place virtually April 24-27. The series titled “A Case Series of the BioTrace Medical Tempo ...
BioStable Science & Engineering, Inc., (“BioStable”) announced today the company has received CE Mark approval for the HAART 200 Aortic Annuloplasty Device for use during bicuspid aortic valve repair. With CE Mark approval of both the HAART 300 and HAART 200 Aortic Annuloplasty Devices, BioStable will be able to offer surgeons within the European Union a comprehensive portfolio of ...